high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13)	placebo on all days	percentages of migrated isoforms (PMI) on days 4 and 11	19076	19201	High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2) % (p<0.00001) and 45.2 (7.3) % (p<0.00001), respectively.
high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13), 	placebo on all days	percentages of migrated isoforms (PMI) on day 25	1229	1385	In both rhEPO groups, PMI on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (p = 0.029); low-dose Epoetin beta: 73.1 (17.8)% (p = 0.039)).
high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13), 	placebo on all days	percentages of migrated isoforms (PMI) on day 25	19564	19750	In both rhEPO groups, PMI on day 25 was still decreased compared with placebo (Figure 3); high-dose Epoetin beta: 72.9 (19.4) (p<0.029) %; low-dose Epoetin beta: 73.1 (17.8) % (p<0.039).
low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13)	placebo on all days	percentages of migrated isoforms (PMI) on days 4 and 11	1118	1228	Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001).
high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13)	placebo on all days	percentages of migrated isoforms (PMI) on days 4 and 11	19076	19290	High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2) % (p<0.00001) and 45.2 (7.3) % (p<0.00001), respectively. PMI differed significantly between all days within the high-dose intervention (p<0.0001)
low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13)	placebo on all days	percentages of migrated isoforms (PMI) on days 4 and 11	19292	19418	Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8) % (p<0.00001) and 46.1 (10.4) % (p<0.00001), respectively.
high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13)	placebo on all days	percentages of migrated isoforms (PMI) on days 4 and 11	-1	-1	PMI after 4, 11 and 25 days of either high-dose rhEPO, low-dose rhEPO, or placebo. N = 15. Values are means with 95 % confidence intervals. *p<0.05; ** p<0.00001 compared with placebo.
